AstraZeneca’s Japan partner to go solo on future cancer drugs
Daiichi Sankyo is expanding its sales and development staff overseas, aiming to boost production capacity so that it can handle its cancer drugs business entirely on its own.
Cancer vaccines poised to unlock 'new treatment paradigm' with Merck-Moderna data
Scientists have been chasing the dream of vaccines to treat cancer for decades with few successes.
Contaminated drugs, shredded papers: U.S. FDA uncovers failures in India pharma factories
Authorities have suspended the licenses of more than a dozen unlisted drugmakers in the wake of dozens of cough syrup deaths.
Obesity and Alzheimer's news makes Eli Lilly world’s most valuable drugmaker
An 8.5% gain in May for Eli Lilly lifted its shares to a record high, while displaced Johnson & Johnson slumped 5.3% during the month.
Doctors in Japan turn to crowdfunding to continue stroke treatment trial
The trial for the drug to treat acute stroke sufferers has hit a snag due to surging import costs, with the price of a vial going from ¥300,000 to ¥1.6 million.
Xylazine spreads faster than U.S. officials can act
The U.S. needs better ways of tracking illicit xylazine, a sedative that’s especially dangerous when mixed with fentanyl.
Scientists urge G7 leaders to improve vaccine access in developing countries
Advocates used the summit to push back against the pharmaceutical industry’s pressure to strengthen intellectual property rights.
Japan has a new vaccine research funding unit for future pandemics — is it up to the task?
The country lacked a sense of urgency to prepare for potential outbreaks — this lack of preparedness has had a lasting impact.
A breakthrough on Alzheimer's is closer than ever
Promising data could open the door to insurance coverage for expensive new Alzheimer's drugs, bringing them closer to patients.
Fentanyl will win the war on drugs
Instead of a hopeless struggle against the supply of fentanyl, the U.S. must focus on reducing demand and the harm.
Drugs developed to treat diabetes may offer new approach against Alzheimer's
Experts hope that by improving glucose metabolism, and tamping down inflammation in the entire body, they can slow progression of diseases like Alzheimer's and Parkinson's.
Experimental Alzheimer's drug slowed disease by 35% in trial, Eli Lilly reports
The results provide what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.
